Mesoblast Ltd Secures Exclusive Rights to a Patented CAR Technology Platform
Mesoblast Ltd (NASDAQ:MESO) has acquired exclusive global rights to a patented CAR technology platform from Mayo Clinic, which could enhance its therapeutic products for diseases like ulcerative colitis and Crohn’s disease. The acquisition was made through a stock transaction, though financial details were not disclosed. The move is expected to improve the targeting and effectiveness of Mesoblast's therapies.
Tickers: $MESO
Topics: biotech CAR technology corporate development licensing MSC therapies